
Advanced Synthesis and Catalysis p. 1567 - 1579 (2006)
Update date:2022-08-05
Topics:
Wang, Dongren
Kroell, Roswitha
Mayr, Monika
Wurst, Klaus
Buchmeiser, Michael R.
The immobilization of both chiral and non-chiral versions of the Schrock catalyst via the arylimido ligand was accomplished for the first time. For this purpose, four different 4-(6-halogenohexyl)-2,6-R2-anilines, i.e., {4-[6-X-(CH2)6]-2,6-R2-C6H 2-NH2} (7: R = Me, X = Br; 8: R = Me, X = Cl, 9: R = 2-Pr, X = Cl, 10: R = 2-Pr, X = Br) were prepared and used for the synthesis of the corresponding Mo-bis(imido)dichloro complexes Mo{N-2,6-R2-4-[6-X- (CH2)6]-C6H2)2Cl 2-DME (11: R = Me, X = Br; 12: R = Me, X = Cl; 13: R = 2-Pr, X = Cl; 14: R = 2-Pr, X = Br). Compounds 11-14 were transformed into the corresponding Mo-bis(imido)dialkyl complexes Mo{N-2,6-R2-4-[6-X-(CH 2)6]-C6H2}2(CH 2CMe2Ph)2 (15: R = Me, X = Br; 16: R = Me, X = Cl, 17: R = 2-Pr, X = Cl; 18: R = 2-Pr, X = Br). These were used for the synthesis of the Mo-imidoalkylidene triflates Mo{N-2,6-R2-4-[6-X- (CH2)6]-C6H2}(CHCMe 2Ph)-(OTf)2·DME (19: R = Me, X = Br; 20: R = 2-Pr, X = Br, 21: R = 2-Pr, X = Cl). Compounds 19-21 were used in the synthesis of the Schrock type catalysts Mo{N-2,6-Me2-4-[6-Br-(CH2) 6]-C6H2} (CHCMe2Ph)[OC(CH 3)(CF3)2]2 (22) and Mo{N-2,6-(2-Pr)24-[6-Cl-(CH2)6]-C 6H2}(CHCMe2Ph)[OC-(CH3)(CF 3)2] (23), Mo{N-2,6-Me2-4-[6-Br-(CH 2)6]-C6H2}(CHCMe2Ph)[(R)- BIPHEN] (24) and Mo{N-2,6-(2-Pr)2-4-[6-Br-(CH2) 6]-C6H2}(CHCMe2Ph)[(R)-BIPHEN] (25). Compounds 22, 24 and 25 were immobilized on Ag-perfluoroalkylsulfonate-modified PS- and PS-DVB materials to yield the corresponding immobilized catalysts Mo{N-2,6-Me2-4-[PS-CH2-O-CF2-CF(CF 3)-SO3-(CH2)6]-C6H 2}(CHCMe2Ph)-[OCMe(CF3)2] 2 (26), Mo{N-2,6-Me2-4-[PS-DVB-CH2-O-CF 2-CF(CF3)-SO3-(CH2) 6]-C6H2} (CHCMe2Ph)[(R)-BIPHEN] (27) Mo{N-2,6-(2-Pr)2-4-[PS-DVB-CH2-O-CF2- CF(CF3)-SO3-(CH2)6]-C 6H2) (CHCMe2Ph)[(R)-BIPHEN] (28). These were used in a series of ring-closing metathesis (RCM), ring-opening cross metathesis, asymmetric RCM and desymmetrization reactions. The use of 27 and 28 resulted in values for enantiomeric excess (ee) virtually identical to those obtained with the corresponding homogeneous chiral catalysts.
View MoreTaizhou Elitechemie MediPharma Technology Co.,Ltd.
Contact:+86-523-86810021
Address:Building G14,NO.1 Avenue,China Medical City, Taizhou, Jiangsu,China
Zibo Kunran Enterprises Co. LTD
website:http://www.kunranchem.com
Contact:0086 533 5200669
Address:No. 96 Jinjing Avenue, Zibo, Shandong, China
Jiangsu Zhenfang Chemical CO.,LTD.(Suzhou Zhenfang Chemical Factory)
Contact:+86-512-69598882
Address:Room1201, Jiayuan Road No.1018, Xiangcheng District, Suzhou, China
Lonzeal Pharmaceuticals Co., Ltd.
website:http://www.lonzeal.com
Contact:+86-13381011962
Address:RM 801, Yue MOMA, No. 26 Anningzhuang Rd. Haidian District, Beijing, China
Contact:Tel:+86-29-88764861 Fax:+86-29-88764861
Address:Rm#2107, Block A, Epin Meidao Building, Gaoxin Rd, Hi-Tech Zone, Xi’an, China
Doi:10.3987/COM-12-S(N)44
(2012)Doi:10.1016/j.ejmech.2013.05.023
(2013)Doi:10.1021/ol401817q
(2013)Doi:10.1021/ol401992s
(2013)Doi:10.1039/c3ra22826f
(2013)Doi:10.1039/c3ra40669e
(2013)